Dermata Therapeutics Inc
NASDAQ:DRMA
Dermata Therapeutics Inc
NASDAQ:DRMA
Price:
1.69
USD
4.97%
Market Cap:
$4.8m
Relative Value
There is not enough data to reliably calculate the relative value of DRMA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DRMA
Relative Value
Base Case
Not Available
Multiples Across Competitors
DRMA Competitors Multiples
Dermata Therapeutics Inc Competitors
Dermata Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
4.8m USD | 0 | -0.5 | -0 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
972.6B USD | 14.9 | 46.9 | 31.7 | 33.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575B USD | 6.2 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.9B CHF | 4.6 | 29.9 | 12.6 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
226.9B GBP | 5.5 | 33.7 | 16 | 23.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.6B CHF | 5.4 | 21.7 | 13.4 | 17.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.5 | 16.2 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.2 | 9.7 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.9B USD | 2.5 | 20.4 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.8B USD | 2.6 | 17.6 | 6.9 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
